You are here: Industry Insights > Sanofi

News List

Sanofi, GSK get approval for Phase 3 COVID-19 vaccine trial in India expresspharma
July 09, 2021
In a two-stage approach, the study will initially investigate the efficacy of a vaccine formulation targeting the original virus strain (D.614), while a second stage will evaluate a second formulation targeting the Beta variant (B.1.351).
Sanofi to license multiple myeloma target domain from Eureka and MSK pharmaceutical-technology
July 08, 2021
Sanofi has signed a licence agreement with Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSK) for non-CAR use of a new human binding domain for the potential treatment of multiple myeloma.
SRI, Sanofi Enter Drug Discovery Collaboration contractpharma
July 08, 2021
Will leverage SynFini, SRI’s artificial intelligence and automation platform to accelerate development of small-molecule drug targets.
France's Sanofi expects Covid vaccine to be ready by December firstwordpharma
July 06, 2021
Sanofi says its GlaxoSmithKline-partnered COVID-19 vaccine should be available by December, reported RFI. The vaccine uses recombinant proteins to trigger an immune response – the same technology that is used in one of Sanofi's seasonal influenza vaccines
Sanofi Launches Dedicated mRNA Vaccines CoE contractpharma
July 01, 2021
Approximately €400million investment annually aims to accelerate end-to-end R&D of next-generation vaccines.
Sanofi plans €400m investment in mRNA vaccines ‘centre of excellence’ pharmatimes
June 30, 2021
French pharma company Sanofi has announced that it will invest €400m into a new facility focused on solely on the development and delivery of next-generation mRNA-based vaccines.
STADA to acquire 16 consumer healthcare brands from Sanofi pharmaceutical-technology
June 30, 2021
Germany-based STADA has agreed to acquire 16 consumer healthcare brands from Sanofi in 13 European markets, including Germany, France, Poland, Italy and Spain.
Sanofi, Regeneron's Libtayo cleared for basal cell carcinoma pharmatimes
June 28, 2021
Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) has won a green light in Europe as the first immunotherapy to treat adults with locally advanced or metastatic basal cell carcinoma (BCC).
Phase I trial of mRNA-based influenza vaccine begins europeanpharmaceuticalreview
June 24, 2021
The trial will assess a monovalent mRNA-based vaccine candidate against seasonal influenza caused by the A/H3N2 strain.
Sanofi and Translate Bio start clinical trial for mRNA flu vaccine expresspharma
June 23, 2021
The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page